Edition:
United Kingdom

Proteon Therapeutics Inc (PRTO.OQ)

PRTO.OQ on NASDAQ Stock Exchange Global Market

2.35USD
17 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.35
Open
$2.35
Day's High
$2.40
Day's Low
$2.35
Volume
3,828
Avg. Vol
4,541
52-wk High
$2.90
52-wk Low
$1.30

Latest Key Developments (Source: Significant Developments)

Proteon Therapeutics Posts Q2 Loss Per Share $0.28
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Proteon Therapeutics Inc ::PROTEON THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.28.Q2 EARNINGS PER SHARE VIEW $-0.36 -- THOMSON REUTERS I/B/E/S.  Full Article

Proteon Therapeutics Q3 ‍loss per share $1.08​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Proteon Therapeutics Inc :Proteon Therapeutics announces third quarter 2017 financial results.Remain on-track to complete enrollment in Q1 of 2018 in patency-2, co's second phase 3 clinical trial of vonapanitase​.Qtrly ‍loss per share $1.08​.Expects its cash, cash equivalents, available-for-sale investments will be sufficient to fund its operations into Q4 of 2019,.Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article

Proteon Therapeutics announces data from trial of investigational vonapanitase in patients with CKD
Tuesday, 13 Dec 2016 

Proteon Therapeutics Inc : Secondary and tertiary endpoint data and enrollment in second phase 3 ongoing . Trial did not meet primary efficacy endpoint .Announces top-line data from phase 3 patency-1 clinical trial of investigational vonapanitase in patients with CKD.  Full Article

Proteon Therapeutics says expects to initiate 2 planned phase 1 clinical studies evaluating vonapanitase in 2016
Tuesday, 25 Oct 2016 

Proteon Therapeutics Inc : Proteon Therapeutics announces overview of phase 1 clinical program of investigational vonapanitase in peripheral artery disease to be presented at the 28th transcatheter cardiovascular therapeutics (TCT) conference .Proteon Therapeutics Inc- company expects to initiate two planned phase 1 clinical studies evaluating Vonapanitase in 2016.  Full Article

  • Previous
  • Next

Proteon Therapeutics Inc News

BRIEF-Proteon Therapeutics Announces Qtrly Loss Per Share $0.34

* PROTEON THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

» More PRTO.OQ News

Earnings vs. Estimates

» More Financials